The uPA (urokinase-type plasminogen activator/PLAU) and its main inhibitor PAI1 play key roles in tumour-associated processes and their elevated expression is correlated with negative outcomes in node negative breast cancer. This evidence concerns the gene PLAU and neoplasm.